EP0556328A4 - Bridging antibody fusion constructs - Google Patents

Bridging antibody fusion constructs

Info

Publication number: EP0556328A4
Authority: EP; European Patent Office
Prior art keywords: antibody fusion; fusion constructs; bridging antibody; bridging; constructs
Prior art date: 1990-11-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19920901152

Other versions

EP0556328A1 (en

Inventor

Stephen D Gillies

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-09

Filing date

1991-11-12

Publication date

1994-06-08

1991-11-12 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1993-08-25 Publication of EP0556328A1 publication Critical patent/EP0556328A1/en

1994-06-08 Publication of EP0556328A4 publication Critical patent/EP0556328A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

EP19920901152 1990-11-09 1991-11-12 Bridging antibody fusion constructs Withdrawn EP0556328A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61211090A	1990-11-09	1990-11-09
US612110		1990-11-09

Publications (2)

Publication Number	Publication Date
EP0556328A1 EP0556328A1 (en)	1993-08-25
EP0556328A4 true EP0556328A4 (en)	1994-06-08

Family

ID=24451769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19920901152 Withdrawn EP0556328A4 (en)	1990-11-09	1991-11-12	Bridging antibody fusion constructs

Country Status (3)

Country	Link
EP (1)	EP0556328A4 (en)
CA (1)	CA2095842A1 (en)
WO (1)	WO1992008801A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
DK1037927T3 (en)	1997-12-08	2004-09-06	Emd Lexigen Res Ct Corp	Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (en)	1999-08-09	2009-05-29	Merck Patent Gmbh	Multiple cytokine−antibody complexes
JP2003514552A (en)	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	Erythropoietin morphology with improved properties
DE60122286T2 (en)	2000-02-11	2007-08-02	Merck Patent Gmbh	INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
ES2288967T3 (en)	2000-06-29	2008-02-01	Merck Patent Gmbh	REINFORCEMENT OF IMMUNE ANSWERS MEDIATED BY THE ANTIBODY-CYTOKIN FUSION PROTEIN THROUGH THE TREATMENT COMBINED BY AGENTS THAT IMPROVE THE INCORPORATION OF IMMUNOCITOQUINE.
BR0207854A (en)	2001-03-07	2004-08-24	Merck Patent Gmbh	Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en)	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
HUP0400284A3 (en)	2001-05-03	2012-09-28	Merck Patent Gmbh	Recombinant tumor specific antibody and use thereof
PL206975B1 (en)	2001-12-04	2010-10-29	Merck Patent Gmbh	Immunocytokines with modulated selectivity
RU2366664C2 (en)	2002-12-17	2009-09-10	Мерк Патент Гмбх	Humanised antibody (h14,18) based on mouse antibody 14,18, contacting gd2, and its fusion with il-2
BRPI0418286A (en)	2003-12-30	2007-05-02	Merck Patent Gmbh	il-7 fusion proteins
CA2551916C (en)	2003-12-31	2014-04-29	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Fc-erythropoietin fusion protein with improved pharmacokinetics
PL1706428T3 (en)	2004-01-22	2010-02-26	Merck Patent Gmbh	Anti-cancer antibodies with reduced complement fixation
RU2437893C2 (en)	2004-12-09	2011-12-27	Мерк Патент Гмбх	Il-7 versions with low immunising capacity
AU2006332138B2 (en)	2005-12-30	2012-03-22	Merck Patent Gmbh	Interleukin-12p40 variants with improved stability
JP2009521912A (en)	2005-12-30	2009-06-11	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	Anti-CD19 antibody with reduced immunogenicity
AU2009308707A1 (en) *	2008-10-31	2010-05-06	Biogen Idec Ma Inc.	LIGHT targeting molecules and uses thereof
EA201171259A1 (en)	2009-04-22	2012-05-30	Мерк Патент Гмбх	ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988009344A1 (en) *	1987-05-21	1988-12-01	Creative Biomolecules, Inc.	Targeted multifunctional proteins
WO1989005816A1 (en) *	1987-12-15	1989-06-29	Protein Design Labs, Inc.	Cellular toxic conjugates
EP0394827A1 (en) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
EP0396387A2 (en) *	1989-05-05	1990-11-07	Research Development Foundation	A novel antibody delivery system for biological response modifiers
WO1991014438A1 (en) *	1990-03-20	1991-10-03	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies with receptor binding ligands in place of their constant region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations

1991
- 1991-11-12 EP EP19920901152 patent/EP0556328A4/en not_active Withdrawn
- 1991-11-12 CA CA 2095842 patent/CA2095842A1/en not_active Abandoned
- 1991-11-12 WO PCT/US1991/008421 patent/WO1992008801A1/en not_active Ceased

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988009344A1 (en) *	1987-05-21	1988-12-01	Creative Biomolecules, Inc.	Targeted multifunctional proteins
WO1989005816A1 (en) *	1987-12-15	1989-06-29	Protein Design Labs, Inc.	Cellular toxic conjugates
EP0394827A1 (en) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
EP0396387A2 (en) *	1989-05-05	1990-11-07	Research Development Foundation	A novel antibody delivery system for biological response modifiers
WO1991014438A1 (en) *	1990-03-20	1991-10-03	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies with receptor binding ligands in place of their constant region

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9208801A1 *

Also Published As

Publication number	Publication date
WO1992008801A1 (en)	1992-05-29
CA2095842A1 (en)	1992-05-10
EP0556328A1 (en)	1993-08-25

Publication	Publication Date	Title
EP0556328A4 (en)	1994-06-08	Bridging antibody fusion constructs
GB2250995B (en)	1994-05-18	Multivalent antigen-binding proteins
GB8820099D0 (en)	1988-09-28	Novel chimeric antibodies
KR960009276B1 (en)	1996-07-16	Double joining roof-structure
AU625613B2 (en)	1992-07-16	Novel chimeric antibodies
GB9112553D0 (en)	1991-07-31	Fusion proteins
IL89491A0 (en)	1989-09-10	Bifunctional chimeric antibodies
GB9015908D0 (en)	1990-09-05	Multivalent immunoglobulin
GB9412166D0 (en)	1994-08-10	Retargetting antibodies
IL96475A0 (en)	1991-08-16	Chimeric proteins
EP0506523A3 (en)	1993-10-20	Monoclonal antibodies
EP0469897A3 (en)	1992-11-19	Engineered antibodies
GB2261623B (en)	1994-06-08	Joining materials
GB9223676D0 (en)	1993-01-06	Modified antibodies
EP0491351A3 (en)	1993-03-17	Chimeric antibodies and their use
GB9014652D0 (en)	1990-08-22	Antigen
GB9115010D0 (en)	1991-08-28	Antibody
ZA912136B (en)	1992-11-25	Anti-oncostatin m monoclonal antibodies
GB8818030D0 (en)	1988-09-01	Fusion constructs
IL98777A0 (en)	1992-07-15	Antibody conjugates
GB9318912D0 (en)	1993-10-27	Humanised antibodies
GB9013419D0 (en)	1990-08-08	Antibodies
IL106427A0 (en)	1993-11-15	Bifunctional chimeric antibodies
IL106429A0 (en)	1993-11-15	Bifunctional chimeric antibodies
IL100926A0 (en)	1992-11-15	Chimeric proteins

Legal Events

Date	Code	Title	Description
1993-07-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1993-08-25	17P	Request for examination filed	Effective date: 19930525
1993-08-25	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
1994-06-01	RHK1	Main classification (correction)	Ipc: C12N 15/62
1994-06-08	A4	Supplementary search report drawn up and despatched	Effective date: 19940420
1994-06-08	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
1996-01-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
1996-01-31	18W	Application withdrawn	Withdrawal date: 19951208